Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Nuvation Bio Inc.NYSE: NUVB
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue declines year over year
Q2 FY2026 cost of revenue of $911K fell 64.6% year over year, behind the -1.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 83.8% from the prior quarter.
Context
- Cost of revenue amounted to 13.4% of revenue in FY2025, down 76.5 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -64.6% toward the trailing-twelve-month pace of -1.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 8.44M USD
- Year-over-year change
- +19.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.44M | +19.3% |
| FY2024 | 2024-12-31 | 7.08M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 cost of revenue of $10.3M is the 3rd highest of the 11 companies compared; the peer median is $2.95M.
- Its year-over-year change of -1.0% is the 3rd highest of 6, against a peer median of -49.7%.
- Cost of revenue amounts to 6.1% of revenue for NUVB, versus a peer median of 25.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $80.53M | — | -24.3% | 118.7% | |
| LTM Jun 2026 | $30.04M | +10.1% | +79.3% | 9.6% | |
| LTM Jun 2026 | $10.3M | -1.0% | — | 6.1% | |
| LTM Mar 2026 | $9.91M | -79.7% | +34.1% | 45.9% | |
| LTM Mar 2026 | $6.64M | +19.4% | +13.1% | 12.8% | |
| LTM Mar 2026 | $4.68M | -49.7% | -20.4% | 25.9% | |
| LTM Jun 2026 | $1.22M | — | — | — | |
| LTM Sep 2026 | $854K | -99.5% | — | 762.5% | |
| LTM Sep 2026 | $590K | — | — | — | |
| LTM Jun 2026 | $320K | — | — | 0.4% | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding NUVB) | $2.95M | -49.7% | +13.1% | 25.9% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.